Astellas acquires Iveric for US$5.9bn
Astellas Pharma has acquired Iveric Bio for US$5.9bn, to further its goal of becoming a world-class ophthalmology entity with a focus on blindness and regeneration, said Astellas in a statement.
The acquisition will absorb US company Iveric’s pipeline, which includes avacincaptad pegol to treat geographic atrophy (GA) (currently under US Food and Drug Administration review) and autosomal recessive Stargardt disease; IC-500, an HtrA1 inhibitor for GA treatment; and gene therapy products mini-CEP290 for Leber congenital amaurosis type 10, mini-ABCA4 for autosomal recessive Stargardt disease and mini-USH2A to treat Usher syndrome type 2A.
Headquartered in Japan, Astellas’ lead ophthalmic product is ASP7317 (human embryonic stem-cell-derived retinal pigment epithelial cells), for the treatment of GA secondary to age-related macular degeneration and Stargardt disease and is in phase 1b clinical trial. Prograf (tacrolimus), an immunosuppressant used in corneal and other organ transplants, is among the company’s existing products.
- Trends in corneal transplantation: beyond 2020June 1, 2023
- Lifestyle costs to our ocular surfaceMay 31, 2023
- RANZCO Vision 2030: providing better vision care in AotearoaMay 31, 2023
- SCC2023 is coming to Sydney!May 30, 2023
- News from ARVO 2023May 30, 2023
- Post-surgery opioids ‘over-prescribed’ in NZMay 29, 2023
- A trip to MorroccoMay 26, 2023
- Stars and their eyes… Rick WakemanMay 25, 2023